Zevra anticipates filing MIPLYFFA sNDA in Q1 2027 as CHMP opinion remains expected in Q4

Seeking Alpha · November 4, 2026, 04:46 UTC

Tickers: $ZVRA

Topics: CHMP opinion drug development sNDA filing

Read the full article at Seeking Alpha

Part of the story Zevra anticipates filing MIPLYFFA sNDA in Q1 2027 as CHMP opinion remains expected in Q4 (2 articles)

More World news

Broadcom Shares Rise Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 19:47 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 Motley Fool · November 12, 2026, 19:48 UTC
Team, Inc. (TISI) Reports Q3 2026 Results Amid Turnaround Deferrals and Geopolitical Disruptions Motley Fool · November 12, 2026, 19:44 UTC
Berkshire Hathaway Stock Reaches Record Levels Amid CEO Greg Abel's Leadership Motley Fool · November 12, 2026, 19:45 UTC
Data I/O Reports Q3 2026 Results Amid V-TEK Acquisition and Automotive Softness Motley Fool · November 12, 2026, 19:45 UTC
Google Unveils Gemini 4 Hydrogen AI Model Optimized for Coding Efficiency Seeking Alpha · November 12, 2026, 19:44 UTC
CMS Announces Final Valuations and Reimbursement Rates for New ESD CPT Codes PR Newswire · November 12, 2026, 19:43 UTC
IRS Announces 2027 Retirement Contribution Limits and Social Security COLA Increase Motley Fool · November 12, 2026, 19:37 UTC
Yesway Reaffirms 2026 EBITDA Guidance and Outlines Texas Allsup’s Conversion Timeline Seeking Alpha · November 12, 2026, 19:40 UTC
Boost Run Reports 496% Year-Over-Year Revenue Growth in Q3 2026 Seeking Alpha · November 12, 2026, 19:40 UTC